Increasing male infertility

Increasing interest in follicle-stimulating hormones

10,000 rises every year in the last five years

Important diagnosis and treatment without gender distinction

As male infertility increases, interest in follicle-stimulating hormone preparations is increasing.

 

So far, women's infertility treatment has been more active than male infertility treatment.

 

93.4%of the cost of infertility, which was carried out by 2021, was used for female infertility patients, and only 6.6%were used for male infertility patients.

 

Infertility can occur in both men and women due to deficiency of sperm formation due to male sperm, mobility, and low pre -stimulating hormonal glands, or ovarian function of women, closure of fallopian tubes, and endometriosis.

 

According to the Social Society of Society of Propaganda (SRS), the cause of infertility is about 40% of male factors.

 

Looking at the number of infertility patients in domestic men, it can be seen that about 43%increased from 6,2468 to 89,350 in five years from 2017 to 2021.

 

On the other hand, female infertility patients increased by about 11% over five years.

 

The reason for the recent increase in male patients who are diagnosed with infertility is that the perception that there may be a cause of infertility is expanded compared to the previous one.

 

Kim Soo -woong, a professor of urology medicine at Seoul National University Hospital, said, “Infight is that infertility is a problem of all couples, and interest in the cause and treatment of male infertility seems to be increasing.

 

"I need a treatment option and research on continuous male infertility treatment is needed." Infertility treatments, which are used in general, have a genital-stimulating hormone.

 

The genital stimulating hormone components include Follicle Stimulating Hormone, Human Menopausal Gonadotropin (HMG), and Human Chorionic Gonadotropin preparations.

 

Among them, the FHS formulation is a hormone that is synthesized and secreted in the pituitary gland, which is not only involved in producing eggs in the ovaries of women but also acts as a hormone that produces sperm in the testicles of men, thereby improving the reproductive function of infertility patients.

 

Among the FSH preparations used in Korea, 'Puregon' is the only man who has an indication of the deficiency of sperm formation caused by men's low -stimulating hormonal glands.

 

PureGon confirmed the effectiveness of the combination of HCG, which was conducted with HCG, which was a lowly stimulating hormonal sexual dysfunction that failed to treat infertility with HCG monotherapy.

 

According to the guidelines of the Endocrinology Society, FSH+HCG combination therapy is essential for men who are reduced in the genitals of the central central central central central central central central central central central central cavity in the treatment of reproductive ability of men.

 

Professor Kim said, “The infertility treatment environment is far from effective infertility through male infertility diagnosis and treatment, and it is increasing the burden on infertility treatment for women.

 

"Everybody needs to be infertile and treated in an appropriate time regardless of gender." World Health Organization (WHO) defines as infertility a couple with a normal marital relationship without contraception who are not pregnant for a year.

 

As of 2021, the number of male and female patients diagnosed with infertility in Korea was about 250,000, up 9% from 2019, and nearly 10,000 people per year for nearly five years.

 

Recently, the city of Seoul also announced a plan to expand infertility support to solve the problem of low outflows.